Patent Classification

Treatment, Obsessive Compulsive Disorders

1. Methods for treating trichotillomania
    
2. Therapy for obsessive compulsive head banging
    
3. Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
    
4. Reboxetine for treatment obsessive compulsive disorders and panic disorder
   
   
5. Methods of treating obsessive-compulsive spectrum disorders

Treatment, Onychomycosis/Nail Related Disorders

1. Method of treating onychomycosis

Treatment, Ophthalmic Related Disorders

1. Methods and compositions for detecting and treating retinal diseases based on metargidin (ADAM-15)
    
2. Ocular gene therapy using avalanche-mediated transfection
    
3. Glycan binding proteins as therapeutic targets for retinal disorders and treatment methods based thereon
    
4. Methods and compositions for treatment of macular and retinal disease
    
5. Viral complement control proteins for eye disorders
    
6. Methods of using zinc containing compounds to improve ocular health
    
7. Methods of screening an agent for an activity in an isolated eye of a teleost
    
8. Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin
    
9. Method of treating a nerve-related vision disorder in a non-diabetic subject
    
10. Methods for treating a corneal disorder and promoting skin wound healing
     
11. Three layer artificial tear formulation
     
12. Methods for treatment of age-related macular degeneration
     
13. Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides
     
14. Treatment method for MMP-implicated pathologies
     
15. Use of lacritin in promoting ocular cell survival
     
16. Treating retinal degeneration caused by retinal vein occlusion or retinal ischemia
     
17. Methods of treating neovascular glaucoma, macular degeneration and capillary proliferation with alphavbeta3-specific antibodies
     
18. Transscleral delivery
     
19. Pharmacological vitreolysis
     
20. Method of generating human retinal progenitors from embryonic stem cells
     
21. Method and composition for the treatment of adenoviral ocular infections
     
22. Method and kit for moisturizing the surface of the eye
     
23. Pharmaceutical compositions comprising cyclosporins
     
24. Treatment of ocular diseases and disorders using lantibiotic compositions
     
25. Methods for treating eye disorders
     
26. Enzymatic treatment of retinitis pigmentosis
     
27. Use of nerve growth factor for the storage, culture or treatment of cornea
     
28. Treatment of retinitis pigmentosa with human umbilical cord cells
     
29. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
     
30. Composition for stabilizing corneal tissue during or after orthokeratology lens wear
     
31. Treatment for dry macular degeneration
     
32. Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides
     
33. Composition for promoting lacrimal secretion
     
34. Diagnostic methods for age related macular degeneration
     
35. Methods and compositions for treating ocular disease
     
36. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
     
37. Detection of proteins whose absence is associated with a neoplasm
     
38. Compositions and methods for treating hyperimmune response in the eye
     
39. Treatment and control of dry eye by use of biodegradable polymer capsules
     
40. Treatment of optic and otic inflammation
     
41. Compositions and methods for the induction of retinal detachments
     
42. Methods and compositions for treating conditions of the eye
     
43. Gold eyelid weight implant
     
44. Gene responsible for Stargardt-like dominant macular dystrophy
     
45. Non-invasive gene targeting to ocular cells
     
46. Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
     
47. Ocular solutions
     
48. Topical treatment for prevention of ocular infections
     
49. Method for growth of human conjunctival tissue equivalents for research, clinical ocular surface transplantation and tissue engineering
     
50. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
     
51. Treatment for dry eye syndrome
     
52. Use of injectable dyes for staining an anterior lens capsule and vitreo-retinal interface
     
53. Diagnostics and therapeutics for macular degeneration-related disorders
     
54. Compositions for treating hyperemia
     
55. Human medical treatment by aerosol inhalation of immunoglobulin A
     
56. Retinal cell grafts
     
57. Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
     
58. Ophthalmic lubricating solution adapted for use in lasik surgery
     
59. Use of Streptomyces hyalurolyticus enzyme in ophthalmic treatments
     
60. Light occlusive patch
     
61. Ophthalmic irrigating solution adapted for use in lasik surgery
     
62. Method for the treatment of bacterial eye infections
     
63. Use of selective PDE IV inhibitors to treat dry eye disorders
     
64. Gene Therapy for proliferative vitreoretinopathy
     
65. Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
     
66. Method of treating eye infections with azithromycin
     
67. Methods and compositions for treating ocular disorders
     
68. Ophthalmic ointments for treating infective eye disease
     
69. Corneal storage fluid comprised of hyaluronic acid
     
70. Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
     
71. Ophthalmic compositions
     
72. Prevention of retinal injury and degeneration by specific factors
     
73. Agents and methods for treatment and diagnosis of ocular disorders
     
74. Ribozyme therapy for the treatment of proliferative skin and eye diseases
     
75. Lens epithelial cell derived growth factor
     
76. Oxazolidinones to treat eye infections
     
77. Biochemical methods that eliminate corneal scars, opacification and haze
     
78. Methods for treating inflammation-mediated conditions of the eye
     
79. Treatment of ocular neovascularization and related diseases
     
80. Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
     
81. Intraocular transplantation of encapsulated cells
     
82. Opthalmologic uses of protein C
     
83. Method of reducing eye irritation
     
84. System and method for treating eye and nerve diseases in diabetic and non-diabetic patients
     
85. Method of treating certain eye diseases
     
86. Reconstructed laminae of human epithelium corneae and method of producing the same
     
87. Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin
     
88. Topical treatment or prevention of ocular infections
     
89. Compositions and methods for treating eye discomfort
     
90. Use of nerve growth factor for the storage, culture or treatment of cornea
     
91. Compositions and methods for treating hyperimmune response in the eye
     
92. Treatment of dry eye syndrome
     
93. Intraocular transplantation of encapsulated cells
     
94. Anti-inflammatory eye drop
     
95. Methods and pharmaceutical compositions for the closure of retinal breaks
     
96. Method for treating meibomian gland disease
     
97. Methods and compositions for the treatment of keratoconus using protease inhibitors
     
98. Selective and non-invasive visualization or treatment of vasculature
     
99. Composition for treatment of an ocular bacterial infection
    
    
100. Histochrome and its therapeutic use in ophthalmology
     
     
101. Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
      
     
102. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
      
     
103. Method for treating ophthalmic disease through fast dispersing dosage forms
      
     
104. Composition for treating dry eye
      
     
105. Ocular gene therapy
      
     
106. Drug composition comprising albumin as active ingredient

Treatment, Osteoporosis

1. Percutaneous delivery system for treatment of osteonecrosis of the hip and methods of use thereof
    
2. Calcium phosphate delivery vehicles for osteoinductive proteins
    
3. Bone delivery conjugates and method of using same to target proteins to bone
    
4. Intracellular delivery of osteoinductive proteins and peptides
    
5. Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
    
6. Osteoprotegerin in milk
    
7. Estrogen receptor alleles that are predictive of increased susceptibility to bone fracture
    
8. Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
    
9. Method for controlling body weight in estrogen-insufficient women
    
10. Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity
     
11. Nasal calcitonin formulation 
     
12. Osteoprotegerin in milk
     
13. Methods useful in the treatment of bone resorption diseases
     
14. Bone precursor cells: compositions and methods
     
15. Effervescent compositions comprising bisphosphonates and methods related thereto
     
16. Composition for an injectable bone mineral substitute material
     
17. Method and compositions for promoting osteogenesis
     
18. Inhibition of PEX in the treatment of metabolic bone diseases
     
19. Agents for treating osteoporosis and inhibiting osteoclast formation
     
20. Targeted delivery of bioactive factors to the systemic skeleton
     
21. Compounds with improved cartilage-inducing and/or bone-inducing activity
     
22. Placental growth factor as a target for the treatment of osteoporosis
     
23. Estrogen receptor alleles that are predictive of increased susceptibility to bone fracture
     
24. Treatment of osteoporosis and autoimmune disease with astrogorgiadiol
     
25. Agents for treating osteoporosis and inhibiting osteoclast formation
     
26. Combination therapy for osteoporosis
     
27. Method of treatment of osteoporosis with compositions of red rice fermentation products
     
28. Method for promoting bone formation
     
29. Agent for the manufacture of biological parts including an active ingredient complex and carrying materials suitable for the active ingredient complex
     
30. Differentiation of adipose stromal cells into osteoblasts and uses thereof
     
31. Method of increasing bone toughness and stiffness and reducing fractures
     
32. Peptide with osteogenic activity
     
33. Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
     
34. Osteoporosis treatment with anti-IL-11 antibody
     
35. Use of calmodulin to promote bone regeneration
     
36. Method of increasing bone toughness and stiffness and reducing fractures
     
37. Treatment of osteoporosis
     
38. Method for treating a disease associated with excessive osteoclast formation
     
39. Plant extracts for the treatment of increased bone resorption
     
40. Hormonal composition consisting of an oestrogen compound and of a progestational compound
     
41. Antibodies associated with alterations in bone density
     
42. Calcium dietary supplement
     
43. Composition for increasing bone density
     
44. Method for diagnosing bone dysbolism
     
45. Plant extracts for the treatment of increased bone resorption
     
46. Method for improving bone mineralization
     
47. Superpotent calcitonin analogs having greatly increased hypocalcemic action in vivo
     
48. Treatment of subnormal bone mineral density
     
49. Method for induction of differentiation of osteoclasts
     
50. Osteoclast secreted chemokine and uses thereof
     
51. Diagnostics and therapeutics for osteoporosis
     
52. Diagnosing an animal for pyrophosphate gout, osteoporosis, or osteoarthritis by assaying intracellular pyrophosphate content in peripheral blood cells
     
53. Nasal calcitonin formulations
     
54. Agent for anti-osteoporosis
     
55. Modified human parathyroid hormone
     
56. Methods for inhibiting bone resorption
     
57. Treatment of skeletal disorders
    
    
58. Treatment or prevention of osteoporosis
     
    
59. Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome
     
    
60. Parathyroid hormone analogues for the treatment of osteoporosis
     
    
61. Treatment of conditions associated with impairment in the level of the parathyroid hormone

Treatment, Otitis Media

1. Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
    
2. Compounds from moraxella catarrhalis
    
3. Composition and method for treatment of otitis media

Treatment, Ovarian Carcinoma

1. Drug resistance and methods of reversing
    
2. Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
    
3. Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
    
4. Detection of ovarian cancer based upon alpha-haptoglobin levels
    
5. Anti-mesothelin antibodies having high binding affinity
    
6. Use of interleukin-19 to treat ovarian cancer
    
7. Antibodies to the K12 protein
    
8. Ovary-specific genes and proteins
    
9. Human ovarian mesothelial cells and methods of isolation and uses thereof
    
10. Methods for the early diagnosis of ovarian cancer
     
11. Methods of detecting cancer based on prostasin
     
12. Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
     
13. Methods for the early diagnosis of ovarian cancer
     
14. Prevention of ovarian cancer by administration of products that induce transforming growth factor-.beta. and/or apoptosis in the ovarian epithelium
     
15. Methods for diagnosing and evaluating cancer
     
16. Compositions and methods for therapy of ovarian cancer
     
17. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
     
18. Compositions and methods for therapy and diagnosis of ovarian cancer
     
19. Compositions and methods for therapy and diagnosis of ovarian cancer
     
20. Sustained GnRH peptide-release formulation
     
    
21. Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof

Treatment, Oxidative Stress/Related Disorders

1. Biomarkers for oxidative stress
    
2. Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators
    
3. Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
    
4. Active oxygen scavenger and cancer chemopreventer from Grifola
    
5. Dendrimer constructs and metal complexes thereof having superoxide dismutase activity

Treatment, Paget's Disease

1. Plant extracts for the treatment of increased bone resorption
    
2. Superpotent calcitonin analogs having greatly increased hypocalcemic action in vivo

Treatment, Pain/Analgesic/Anesthetic

1. Diclofenac sodium patches for topical treatment of pain
    
2. Gene expression and pain
    
3. Topical pain reliever and method of making the same
    
4. Method for reducing pain with ziconotide and morphine
    
5. Use of neurotoxic substances for the production of a means for the treatment of joint pain and method for application of said means
    
6. Method for reducing pain with ziconotide and baclofen
    
7. Method for preventing or treating neuropathic pain
    
8. Gene expression and pain
    
9. Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
    
10. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
     
11. Biomarkers of chronic pelvic pain syndrome
     
12. Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
     
13. Ternary and quaternary eutectic mixtures of local anesthetics substances
     
14. Opioid agonist/antagonist combinations
     
15. Method of treating post-surgical acute pain
     
16. Lactoferrin in the reduction of pain
     
17. Clostridial toxin derivatives and methods for treating pain
     
18. Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
     
19. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
     
20. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
     
21. Pharmaceutical formulation comprising ziconotide
     
22. Controlled release hydrocodone formulations
     
23. Method for treating pain with prolactin antagonists
     
24. Methods for treating myofascial pain
     
25. Medicinal uses of mu-opioid receptor agonists
     
26. Methods and compositions for deterring abuse of opioid containing dosage forms
     
27. Delivery of opioids through an inhalation route
     
28. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
     
29. Opioid agonist/antagonist combinations
     
30. Treatment of a facial pain by peripheral administration of a neurotoxin
     
31. Liposomal analgesic drug compositions prepared in GMV using an ammonium sulfate gradient
     
32. .alpha.-conotoxin peptides with analgesic properties
     
33. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
     
34. Lactoferrin in the reduction of pain
     
35. Method for treating allodynia by peripheral administration of a neurotoxin
     
36. Method for treating phantom pain by peripheral administration of a neurotoxin
     
37. Sustained release formulations of oxymorphone
     
38. Orally administrable opioid formulations having extended duration of effect
     
39. Transdermal buprenorphine dosage regimen for analgesia
     
40. Therapeutic compositions for intranasal administration which include KETOROLAC
     
41. Clostridial toxin derivatives and methods for treating pain
     
42. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist
     
43. Compositions and medical device for transdermal delivery of a drug and methods of making and using same
     
44. Clostridial toxin derivatives and methods for treating pain
     
45. Strontium compound for treatment of sub-dermal soft tissue pain
     
46. Analgesic from snake venom
     
47. Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
     
48. Post-operative pain treatment by peripheral administration of a neurotoxin
     
49. Opioid agonist / antagonist combinations
     
50. Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities
     
51. Topical analgesic and methods of use
     
52. Clostridial toxin derivatives and methods for treating pain
     
53. Pain management composition comprising plant extracts
     
54. Opioid agonist in a fast dispersing dosage form
     
55. Methods for treating arthritis pain
     
56. Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
     
57. Composition comprising a tramadol material and acetaminophen and its use
     
58. Method for treating post herpetic neuralgia by peripheral administration of a neurotoxin
     
59. Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
     
60. Composition for pain mediation and apparatus and method of use thereof
     
61. Buccal, polar and non-polar spray or capsule containing drugs for treating painBuccal, polar and non-polar spray or capsule containing drugs for treating pain
     
62. Tape material for transcutaneous absorption
     
63. Liposomal analgesic formulation and use
     
64. Liposomak compositions and methods of preparation
     
65. Formulations and methods for providing prolonged local anesthesia
     
66. Transdermal delivery system for alkaloids of aconitum species
     
67. Local anesthetic methods and kits
     
68. Pain treatment by peripheral administration of a neurotoxin
     
69. Delivery of analgesics through an inhalation route
     
70. Pharmaceutical compositions for buccal delivery of pain relief medications
     
71. Plaster containing felbinac
     
72. Composition and method for treating the effects of diseases and maladies
     
73. Method of administering high-dose, oral magnesium for treatment of chronic pain syndrome of erythromelalgia
     
74. Pain reliever and method of use
     
75. Opioid analgesic
     
76. Topical application of opioid analgesic drugs such as morphine
     
77. Delivery of opioids through an inhalation route
     
78. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
     
79. Extracts of celery seed for the prevention and treatment of pain, inflammation and gastrointestinal irritation
     
80. LIF for use in modulating inflammation and pain
     
81. Intradermal-penetration agents for topical local anesthetic administration
     
82. Melt-extruded orally administrable opioid formulations
     
83. Iontophoresis disc pain blocker
     
84. Process and composition for temporarily suppressing pain
     
85. Boric acid analgesic composition and method of treatment using the same
     
86. Method of treating chronic pain
     
87. Methods for providing safe local anesthesia
     
88. Tamper-resistant oral opioid agonist formulations
     
89. Devices and methods for pain management
     
90. Opioid analgesics with controlled active substance release
     
91. Use of inhibitors of protein kinase C epsilon to treat pain
     
92. Pain management with liposome-encapsulated analgesic drugs
     
93. Method for treating a cholinergic influenced sweat gland
     
94. Methods comprising intranasal morphine
     
95. Transdermal and topical administration of local anesthetic agents using basic enhancers
     
96. Selenocosmia huwena toxin and analgesic uses thereof
     
97. Formulation for respiratory tract administration
     
98. Use of melatonin analogues for induction of general anesthesia
     
99. Topical compositions and methods for treating pain
     
100. Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
      
101. Use for pain management
      
102. Method for alleviating pain or providing an analgesic effect in a patient
      
103. Analgesics combined with naturally-occurring chondroprotective agents
      
104. Analgesic regimen
      
105. Method of local anesthesia and analgesia
      
106. Method for treatment of pain
      
107. Method for preventing or treating pain by administering an endothelin antagonist
      
108. Prolonged anesthesia in joints and body spaces
      
109. Formulations and methods for providing prolonged local anesthesia
      
110. Methods and compositions for treating pain of the mucous membrane
      
111. Clostridial toxin derivatives and methods for treating pain
      
112. Analgesic screening method and composition
      
113. Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold
      
114. Method for treating pain by peripheral administration of a neurotoxin
      
115. Compositions and methods comprising morphine gluconate
      
116. Transplantation of neural cells for the treatment of chronic pain or spasticity
      
117. Process and composition for temporarily suppressing pain
      
118. Formulations and methods for providing prolonged local anesthesia
      
119. Triple drug therapy for the treatment and prevention of acute or chronic pain
      
120. Topical dermal anaesthetic
      
121. Use of conantokins for producing analgesia or for neuoprotection
     
     
122. Use for pain management
     
     
123. Opioid agonist/opioid antagonist/acetaminophen combinations
     
     
124. Use of inhibitors of protein kinase C epsilon to treat pain
     
     
125. Intraspinal botulinum toxin for treating pain
     
     
126. Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
     
     
127. Analgesic use of podophyllotoxin for treating pain conditions in female genital organs
     
     
128. System for percutaneous delivery of opioid analgesics
     
     
129. Pain relief preparation for use while bathing
     
     
130. Analgesic regimen
      
     
131. Pharmaceutical formulations comprising vegetal material selected from trichilia 
      
132. Therapeutic compositions for intranasal administration which include KETOROLAC.RTM.
      
     
133. Preemptive analgesic agent and methods of use
      
     
134. Clear, injectable formulation of an anesthetic compound
      
     
135. Herbal composition to relieve pain
      
     
136. Mu-opiate receptor peptides
      
     
137. Enhanced transdermal anesthesia of local anesthetic agents
      
     
138. Methods and apparatus for improved administration of fentanyl and sufentanil
      
     
139. Topical anesthetic patch
      
     
140. Administration of ketamine to manage pain and to reduce drug dependency
      
     
141. Composition of S-sodium ibuprofen
      
     
142. High load formulations and methods for providing prolonged local anesthesia
      
     
143. Intraspinal methods for treating pain
      
     
144. Biodegradable polymer matrices for sustained delivery of local anesthetic agents
      
     
145. Use of antidepressants for local analgesia

Treatment, Pancreatic Disorders/Cancer

1. Combination of an anti-ED--B fibronectin domain antibody--IL-2 fusion protein and gemcitabine
    
2. Pancreatic cancer genes
    
3. Drug and food or drink for improving pancreatic functions
    
4. Treating abdominal pain due to pancreatitis with seaprose
    
5. Methods for diagnosis and therapy of pancreatic cancer and composition useful therein
    
6. Method of forming vertebrate pancreas in vitro
    
7. Combinatorial methods for inducing cancer cell death
    
8. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    
9. Monoclonal antibody hPAM4
    
10. Methods and compositions for the treatment of pancreatitis
     
11. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
     
12. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
     
13. Methods and compositions for the treatment of pancreatitis
     
14. Methods of making pancreatic islet cells
     
15. Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
     
16. Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
     
17. Agent for ameliorating pancreatic function disorder
     
18. Pancreatic cancer genes
     
19. Method of treating cancer with anti-neurotrophin agents
     
20. Methods of culturing and encapsulating pancreatic islet cells
    
    
21. Method for treating a pancreatic disorder with a neurotoxin
     
    
22. Immobilization of lipases by entrapment in silica matrices

Treatment, Panic Disorders

1. Polymorphic DNAs and their use for diagnosis of susceptibility to panic disorder
    
2. Reboxetine for treatment obsessive compulsive disorders and panic disorder

Treatment, Papillomavirus Infections

1. Papillomavirus vaccines
    
2. Compositions and methods for treating papillomavirus-infected cells
    
3. Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors
    
4. Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
    
5. Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
    
6. Mixed Virus-like particles
    
7. Treatment of HPV caused diseases
    
8. Treatment of papillomavirus infections
    
9. Synthetic human papillomavirus genes
    
10. Treatment of papilloma virus infection using a mycobacterium
     
11. Formalin-treated human papillomavirus L1 protein vaccine
     
12. Treatment of papillomavirus infections
     
13. Method for treating papillomavirus infections

Treatment, Parasitic Infections

1. Active compound-containing solid moulded bodies for external use against parasites on animals
    
2. Piroplasmid vaccine
    
3. Compositions and methods for treating intracellular diseases
    
4. Cytokine activity regulator molecules from tick salivary glands
    
5. Topical endoparasiticide and ectoparasiticide formulations
    
6. Process for the in vitro culture of different stages of tissular parasites
    
7. M. canis-containing ringworm vaccine
    
8. Recombinant P. falciparum merozoite protein-1.sub.42 vaccine
    
9. Antigen fragments for the diagnosis of Toxoplasma gondii
    
10. Human hookworm model and method for maintaining human hookworm in a non-human primate
     
11. Medicament for the treatment of diseases caused by parasitic protozoa
     
12. Coccidiosis vaccines
     
13. Methods and compositions for detecting larval Taenia solium with a cloned diagnostic antigen
     
14. Topical ivermectin composition
     
15. Serine-threonine phosphatase protein of a parasitic organism of the Apicomplexa phylum, applications in therapeutics
     
16. Plasmodium falciparum antigens inducing protective antibodies
     
17. Ectoparasiticidal aqueous suspension formulations of spinosyns
     
18. Diagnostic assays for detection of Giardia lamblia
     
19. Prophylactic and therapeutic immunization against protozoan infection and disease
     
20. Pharmacological targeting of mRNA cap formation for treatment of parasitic infections
     
21. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
     
22. Compositions and methods for detecting adult Taenia solium
     
23. Antiparasitic formulation
     
24. Compositions of parasitic helminth PLA2 nucleic acid molecules and uses thereof
     
25. Injectable anthelmintic compositions and methods for using same
     
26. Antiparasitic helminth larval thiol specific antioxidant-antibodies, and uses thereof
     
27. Spot-on formulations for combating parasites
     
28. Parasitic nematode transglutaminase proteins and uses thereof
    
    
29. Parasitic helminth DiAg2 proteins and uses thereof

Treatment, Parathyroidism, Hyper/Hypo; Thyroid Disorders/Cancer

1. Antibodies against human parathyroid hormone related protein
    
2. Pharmaceutical formulae for thyroid hormones and procedures for obtaining them
    
3. Human chorionic gonadotropin superagonists
    
4. Method for distinguishing follicular thyroid adenoma (FTA) from follicular thyroid carcinoma (FTC)
    
5. Apparatus and method for transdermal delivery of parathyroid hormone agents 
    
6. Pulmonary delivery of active fragments of parathyroid hormone
    
7. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
    
8. Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
    
9. Antibodies against human parathyroid hormone related protein
    
10. Methods of use for antibodies against parathyroid hormone
     
11. Method for distinguishing follicular thyroid adenoma (FTA) from follicular thyroid carcinoma (FTC)
     
12. Pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration comprising the component
     
13. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
     
14. Storage stable thyroxine active drug formulations and methods for their production
     
15. Iodine uptake restoration in thyroid cancer
     
16. Stabilization of solid thyroid drug formulations
     
17. Clostridial toxin therapy for Hashimoto's thyroiditis
     
18. Botulinum toxin therapy for Hashimoto's thyroiditis
     
19. Method for treating hyperthyroidism
     
20. Method for treating thyroid disorders with a botulinum toxin
     
21. Method for treating hypocalcemia
     
22. Method for treating hypocalcemia
     
23. Hypoparathyroid therapy
     
24. Stabilized thyroxine compounds
     
25. Method for treating hypothyroidism
     
26. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
     
27. Human thyroid protein ZSIG45
     
28. Antibodies and methods of making antibodies to human thyroid protein zsig45
     
29. Liquid pharmaceutical compositions comprising thyroid hormones
     
30. Modified human parathyroid hormone
     
31. Parathyroid hormone-related peptide analogs
    
    
32. Method for treating Hashimoto's thyroiditis
    
    
33. Method for treating hyperparathyroidism

Treatment, Parkinson's Diseases/Dyskinesia

1. Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
    
2. Pulmonary delivery for levodopa
    
3. Treatment of Parkinson's disease and related disorders using postpartum derived cells
    
4. Hepatocyte growth factor gene therapy for parkinson's disease
    
5. Method of treating Parkinson's disease
    
6. Prediction of Parkinson's disease using gene expression levels of peripheral blood samples
    
7. Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
    
8. Combined therapy for the treatment of parkinson's disease
    
9. Nucleic acids encoding respiratory syncytial virus subgroup B strain 9320
    
10. Methods of inhibiting amyloid toxicity
     
11. Delivery of compounds for the treatment of Parkinson's through an inhalation route
     
12. Transdermal therapeutic system for treating Parkinsonism
     
13. Sporoderm-broken germination-activated ganoderma lucidum spores for protection of dopaminergic neurons and treatment of Parkinson's disease
     
14. Matrix controlled transdermal therapeutic system for the use of pramipexole and ropinirole
     
15. Methods and kit for treating Parkinson's disease
     
16. Vesicular monoamine transporter gene therapy in parkinson's disease
     
17. Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry
     
18. Mutant NURR1 gene in Parkinson's disease
     
19. Cloning of a gene mutation for parkinson's disease
     
20. Pulmonary delivery in treating disorders of the central nervous system
     
21. Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
     
22. Rodent model for Parkinson's Disease
     
23. Production of tyrosine hydroxylase positive neurons
     
24. Methods for therapy of neurodegenerative disease of the brain
     
25. Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
     
26. Cell expansion system for use in neural transplantation
     
27. Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
     
28. Treatment of dyskinesia
     
29. Nasal delivery of apomorphine
     
30. Parkinson's disease treatment
     
31. Pulmonary delivery in treating disorders of the central nervous system
     
32. Therapeutic uses of melatonin
     
33. Therapeutic Gene
     
34. Pulmonary delivery in treating disorders of the central nervous system
     
35. Vesicular monoamine transporter gene therapy in Parkinson's disease
     
36. Method for increasing the concentration of ascorbic acid in brain tissue of a subject
     
37. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
     
38. Combinations of riluzole and levodopa for the treatment of Parkinson's disease
    
    
39. Method for treatment of a neurological disease characterized by impaired neuromodulator function
    
    
40. Method of controlling L-Dopa production and of treating dopamine deficiency
     
    
41. Method for treating parkinson's disease with a botulinum toxin
     
    
42. Method for generating dopaminergic cells derived from neural precursors
     
    
43. Methods for treating Parkinson's disease using optically pure (-)-bupropion
     
    
44. Intestinal absorption of nicotine to treat nicotine responsive conditions
     
    
45. Methods and apparatus for treatment of Parkinson's disease

Treatment, Patient/Drug Information Management

1. Providing patient-specific drug information

Treatment, Peptic Ulcer

1. Phytodrug for management of peptic ulcer and methods of preparing and using same
   
   
2. Chinese drug composition for treatment of peptic ulcer and preparation thereof

Treatment, Periodontal/Dental Diseases/Care

1. Formulations and methods for recovery from dental surgery
    
2. Particles that disrupt or impede bacterial adhesion, related compositions and methods
    
3. Agent for dissolving dental calculi and dental caries
    
4. Oral killed vaccines and method for providing same
    
5. Use of osteopontin in dental formulations
    
6. Methods of detecting Charcot-Marie Tooth disease type 2A
    
7. Agent against periodontal disease
    
8. Dental restorative materials
    
9. Staining agent in tablet form for making visible the formation of dental plaque and method for producing such a staining agent
    
10. Method for treating periodontal disease with a bacteriocidal disinfectant
     
11. Antibacterial dentifrice exhibiting antiplaque and breath freshening properties
     
12. Method of enhancing fluoridation and mineralization of teeth
     
13. Vaccine for periodontal disease
     
14. Chewable antiplaque confectionery dental composition
     
15. Computer-implemented system and method for automated and highly accurate plaque analysis, reporting, and visualization
     
16. Calcium phosphopeptide complexes
     
17. Photosensitizer conjugates for pathogen targeting
     
18. Method and composition for treating periodontal disease
     
19. Enzyme containing oral composition having enhanced stability
     
20. Methods of treatment of periodontal disease
     
21. Porphyromonas gingivalis recombinant proteins and truncations
     
22. Toothpaste containing anticancer agents
     
23. Preventing tooth decay and infective endocarditis using natural oligopeptides
     
24. Pretreatment kit for saliva and pretreatment method for saliva
     
25. Glucosyltransferase immunogens
     
26. Fast dissolving orally consumable films
     
27. Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
     
28. Method and apparatus for preventing tooth decay
     
29. Method for preparing a calcium phosphate pasty material for injection
     
30. Stomatic composition
     
31. Liquid oral compositions comprising a calcium compound and an acidulant
     
32. Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
     
33. Polymethylmethacrylate augmented with carbon nanotubes
     
34. Local anesthetic methods and kits
     
35. Synthetic peptide vaccines for dental caries
     
36. Use of gellable pharmaceutical compositions in periodontology
     
37. Compounds for treating fungal pathologies of the oral cavity
     
38. Calcium phosphopeptide complexes
     
39. Edible film formulations containing maltodextrin
     
40. Method for transforming cariogenic food sugars into acariogenic or cariostatic neutral products and composition therefor
     
41. Remedies for periodontosis
     
42. Composition and method for promoting oral health
     
43. Antibiotic/medicated gutta percha point
     
44. Animal model for detection of vulnerable plaques
     
45. Enzyme capable of hydorlyzing plaque, microorganism producing the same, and a composition comprising the same
     
46. Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
     
47. Topical dermal anaesthetic
     
48. Use of bacterial phage associated lysing enzymes for treating bacterial infections of the mouth and teeth
     
    
49. Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
     
    
50. Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof

Treatment, Pertussis/Whooping Cough

1. Acellular pertussis vaccines and methods of preparation thereof

Treatment, Peyronie's Disease

1. Composition and method for treating peyronie's disease and related fibrotic tissue disorders

Treatment, Phenylketonuria

1. Nutritional formula for phenylketonuria patients

Treatment, Photodynamic Therapy

1. Intracorporeal medicaments for photodynamic treatment of disease
    
2. Photochemical internalization for virus-mediated molecule delivery into the cyosol
    
3. Noninvasive vascular therapy
    
4. Photoimmunotherapies for cancer using combination therapies
    
5. Intracorporeal medicaments for photodynamic treatment of disease
    
6. Intracorporeal medicaments for photodynamic treatment of disease
    
7. Method for photodynamic therapy and applicator for carrying out said therapy
    
8. Composition and method for causing photodynamic damage to target cells

Treatment, Polycystic Ovarian Disease

1. Kit for use in treatment of polycystic ovarian disease

Treatment, Pregnancy, Complications/Pre-eclampsia/Related Disorders

1. Method for extending pregnancy in patients exhibiting at least one symptom of preeclampsia and eclampsia
    
2. Non-invasive detection of fetal genetic traits
    
3. Compounds useful in the diagnosis and treatment of pregnancy-associated malaria
    
4. Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
    
5. Methods of diagnosing and treating pre-eclampsia or eclampsia
    
6. Use of hCG in controlled ovarian hyperstimulation
    
7. Method for predicting pregnancy-induced hypertension
    
8. Methods of treating pre-eclampsia or eclampsia
    
9. Multi-marker screening protocol for fetal abnormalities
    
10. Nutritional supplements
     
11. Method and apparatus for detecting conception in animals
     
12. Diagnostic method for screening complement regulatory protein levels to predict spontaneous abortion
     
13. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
     
14. Predictive test for pre-eclampsia
     
15. Diagnosis of pre-eclampsia
     
16. Vaginal pH buffering for preventing miscarriage and premature labor, by treating or preventing bacterial vaginosis
     
17. Endometrial function
     
18. Methods and compositions for the selective regulation of chorionic prostanoids
     
19. Repair of ruptured membrane by injection of naturally occurring protein in amniotic fluid sac

Treatment, Prematurely Born Neonate/Prenatal Related Disorders

1. Marker for prenatal diagnosis and monitoring
    
2. Use of xenon with hypothermia for treating neonatal asphyxia
    
3. Determination of risk and treatment of complications of prematurity
    
4. Modified vaccinia virus ankara for the vaccination of neonates
    
5. Materials and methods for providing nutrition to neonates
    
6. In utero oral nucleic acid immunization
    
7. Externally applied medicine for baby's hernia
    
8. Method for treating respiratory distress syndrome
    
9. Product and method for swelling a cell nucleus without DNA replication
    
10. Method to reduce the incidence of intraventricular hemorrhage in preterm infants
     
11. Method of preventing retinopathy of prematurity in a neonate

Treatment, Premenstrual Disorders

1. Method of preparing and using compositions extracted from vegetable matter for the treatment of female symptoms
    
2. PMS defense: an aromatherapy compound for the relief of symptoms of premenstrual syndrome
    
   
3. Method for treating symptoms associated with premenstrual syndrome by administering a combination of calcium and vitamin D

Treatment, Probiotic Therapy

1. Probiotic therapy for newborns

Treatment, Progestin Therapy

1. Progestin therapy for maintaining amenorrhea

Treatment, Prostate Cancer/Hypertrophy/Related Disorders

1. 84P2A9: a prostate and testis specific protein highly expressed in prostate cancer
    
2. Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
    
3. Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA
    
4. Prostate cancer vaccine
    
5. Isolated human antibodies that bind epitopes on RG1
    
6. Breast, gastric and prostate cancer associated antigens and uses therefor
    
7. Markers of DNA copy number alteration for improved prognostication in prostate cancer
    
8. Generation of immune response to prostate-specific antigen (PSA)
    
9. Mouse models of human prostate cancer
    
10. Reagents and methods for inducing an immune response to prostate specific antigen
     
11. Immunogenic peptides for the treatment of prostate and breast cancer
     
12. Tissue specific prodrugs
     
13. Process for delivery of polynucleotides to the prostate
     
14. Prostate-specific polypeptide pamp and encoding nucleic acid molecules
     
15. Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer
     
16. Prostate cancer specific internalizing human antibodies
     
17. RG1 antibodies and uses thereof
     
18. Diagnosis of disease state using mRNA profiles in peripheral leukocytes
     
19. Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
     
20. Prostate cancer cell lines
     
21. Treatment and diagnosis of cancer
     
22. Antibodies that recognize and bind phosphorylated human androgen receptor and methods of using same
     
23. Mouse models of human prostate cancer
     
24. Treatment and diagnosis of prostate cancer
     
25. Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin
     
26. Compositions and methods for therapy and diagnosis of prostate cancer
     
27. Sequences for targeting metastatic cells
     
28. Neuroendocrine marker of prostate cancer and method for producing same
     
29. Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
     
30. Use of human prostrate cell lines in prostate cancer treatment
     
31. Methods of assessing the effect of a gene of interest on human prostate cancer progression
     
32. Method and composition for treating prostate cancer
     
33. DNA encoding the prostate-specific membrane antigen-like gene and uses thereof
     
34. Method of identifying and treating invasive carcinomas
     
35. Methods of diagnosing prostate cancer through the detection of the presence or absence of Pax 2 mRNA
     
36. Diagnostic for metastatic prostate cancer
     
37. Methods and compositions for the treatment of benign prostatic hypertrophy
     
38. Methods of simulating human prostate cancer progression
     
39. Composition and method for inducing apoptosis in prostate cancer cells
     
40. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
     
41. Prostate cancer cell lines
     
42. Polymeric delivery formulations of leuprolide with improved efficacy
     
43. Notch receptor agonists and uses
     
44. Methods for diagnosing and evaluating cancer
     
45. Methods and compositions for inhibiting the proliferation of prostate cancer cells
     
46. Compounds for immunotherapy of prostate cancer and methods for their use
     
47. Methods and compositions for inhibiting the proliferation of prostate cancer cells
     
48. Method for chemoprevention of prostate cancer
     
49. Compounds for immunotherapy of prostate cancer and methods for their use
     
50. Use of a Serenoa repens extract for the production of a medicament to treat prostate cancer
     
51. Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
     
52. Method of treating cancer with anti-neurotrophin agents
     
53. Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug
     
54. Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer
     
55. Use of garlic extract as both preventive and therapeutic agents for human prostate and bladder cancers
     
56. Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer
    
    
57. Uteroglobin gene therapy for epithelial cell cancer
    
    
58. Method of treating cancer of the prostate
    
    
59. Mice models of human prostate cancer progression
    
    
60. Sustained GnRH peptide-release formulation
     
    
61. Method of inducing apoptosis in cancer cells using an extract of Melothria indica Lou
     
    
62. Composition for treating benign prostatic hypertrophy
     
    
63. Localization and therapy of non-prostatic endocrine cancer with agents directed against prostate specific antigen
     
    
64. Prostate cancer gene
     
    
65. Compounds for immunotherapy of prostate cancer and methods for their use

Treatment, Protozoan Infections

1. Anti-protozoan methods and materials

Treatment, Pseudomonas aeruginosa

1. Pseudomonas treatment composition and method

Treatment, Psoriasis/Eczema

1. Treating eczema and/or psoriasis
    
2. Soluble heterodimeric cytokine receptor
    
3. Topical treatment for psoriasis
    
4. Methods of treating psoriasis with .alpha..sub.v.beta..sub.3-specific antibodies
    
5. Method for treating psoriasis by administering an anti-il-12 antibody
    
6. Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
    
7. Compositions and methods for diagnosing or treating psoriasis
    
8. Skin penetration enhancing components
    
9. Method of testing for psoriasis vulgaris
    
10. Multi-purpose skin balm including skin balm for psoriasis
     
11. Treatment of psoriasis using anti-B7.1 (CD80) antibodies
     
12. Chinese herbal composition for treating eczema and psoriasis
     
13. Topical composition for the treatment of psoriasis and related skin disorders
     
14. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
    
    
15. Chinese herbs extract
    
    
16. Topical medicament for the treatment of psoriasis
    
    
17. Betamethasone- and hyaluronic acid-treated thin adhesive plaster for the treatment of psoriasis dermatitis and dermatosis
    
    
18. Methods and compositions for the treatment of psoriasis

Treatment, Psychiatric/Psychological Disorders

1. Antibody for diagnosing neuropsychiatric diseases, in particular schizophrenia, depression and bipolar affective disorders
    
2. Methods for the treatment of mood disorders
    
3. Delivery of antipsychotics through an inhalation route
    
4. Method for diagnosing or predicting susceptibility to psychiatric disorders
    
5. Method for classification of anti-psychotic drugs
    
6. Identification of ligands by selective amplification of cells transfected with a 5HT2A receptor
    
7. Therapeutic treatments for repetitive hand washing
    
8. Peptides for the diagnosis of schizophrenia
    
9. Herbal formulation for treatment of depression and other related disorders and method of preparing the same
    
10. Gene, disrupted in schizophrenia
     
11. Methods and compositions for screening of human borna disease virus
     
12. Use of SLURP-1 compositions for treating schizophrenia
     
13. Detection of antidepressant induced mania
     
14. Osmotic device containing venlafaxine and an anti-psychotic agent
     
15. Method of determining susceptibility to bipolar disorders
     
16. Methods for selecting a therapy for a subject suffering from schizophrenia
     
17. Delivery of antidepressants through an inhalation route
     
18. Combination of cyamemazine and an atypical neuroleptic
     
19. Methods for preventing antipsychotic-induced weight gain
     
20. Use of molindone to treat oppositional defiant disorder and conduct disorder
     
21. Quetiapine granules
     
22. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
     
23. Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
     
24. Cleavage system inhibitors as potential antipsychotics
    
    
25. Method and devices for transdermal delivery of lithium
    
    
26. Glycine substitutes and precursors for treating a psychosis
    
    
27. Adhesive patch for lithium controlled release

Treatment, Pulmonary/Respiratory Related Disorders

1. Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation
    
2. N protein mutants of porcine reproductive and respiratory syndrome virus
    
3. Preventing airway mucus production by administration of EGF-R antagonists
    
4. Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
    
5. System and methods of maintaining space for augmentation of the alveolar ridge
    
6. Use for budesonide and formoterol
    
7. Methods for treatment of severe acute respiratory syndrome (SARS)
    
8. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
    
9. Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
    
10. Methods and devices for treating lung dysfunction
     
11. Antibodies against and methods for producing vaccines for respiratory syncytial virus
     
12. Treating severe acute respiratory syndrome
     
13. Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
     
14. Detecting a bacterial process in chronic rhinosinusitis
     
15. Methods and compositions for Mycoplasma pneumoniae exotoxins
     
16. Use of hyperpolymeric hemoglobin for the treatment of pulmonary edema
     
17. High storage stability inhalable compositions
     
18. Liquid drug preparations
     
19. Methods and compositions for using aleveolar macrophage phospholipase A2
     
20. Anti-virus therapy for respiratory diseases
     
21. Lung volume reduction using glue composition
     
22. Treatment of acute lung injury, fibrosis and metastasis with antagonists of .alpha.v.beta.6
     
23. Hypertonic solutions and method of treatment
     
24. Method of generating and/or increasing an immune response against RSV
     
25. Full-length interferon gamma polypeptide variants
     
26. Methods for promoting, inhibiting and detecting toxin entry into cells
     
27. Methods for treating illnesses of the tracheo-bronchial tract, especially chronic obstructive pulmonary disease (COPD)
     
28. Glue composition for lung volume reduction
     
29. Polynucleotides encoding recombinant respiratory syncytial viruses expressing immune modulatory molecules
     
30. Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
     
31. AAV vectors for gene delivery to the lung
     
32. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
     
33. Aerosol formulations and aerosol delivery of scopolamine
     
34. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
     
35. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
     
36. Base material for regenerating an air sinus and regeneration method thereof
     
37. Subunit vaccine against respiratory syncytial virus infection
     
38. Carbon dioxide enhancement of inhalation therapy
     
39. Preventing airway mucus production by administration of EGF-R antagonists
     
40. Attenuated vaccine useful for immunizations against Coccidioides spp. infections
     
41. CXCL10-based diagnosis and treatment of respiratory illnesses
     
42. Methods and compositions for using alveolar macrophage phospholipase A2
     
43. Stabilized liquid anti-RSV antibody formulations
     
44. Infectious bronchitis virus vaccine
     
45. Inhalation particles incorporating a combination of two or more active ingredients
     
46. Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
     
47. Treatment of respiratory disease
     
48. Extraneous DNA sequence that facilitates hantavirus gene expression
     
49. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
     
50. Biological compositions and methods for treatment of lung cancer
     
51. Use of bacterial phage associated lysing enzymes for treating upper respiratory illnesses
     
52. Recombinant SP-A for the treatment or prevention of pulmonary infection and inflammation
     
53. Stabilized liquid anti-RSV antibody formulations
     
54. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
     
55. Gene expression vaccine
     
56. Inactivated respiratory syncytial viral vaccines
     
57. Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
     
58. Use of pulmonary surfactant
     
59. Temperature-sensitive and cold-adapted human parainfluenza virus type 2 (HPIV-2) and vaccines based on such virus
     
60. Medicine response assay in respiratory disease
     
61. Enhancing therapeutic effectiveness of nitric oxide inhalation
     
62. Human medical treatment by aerosol inhalation of immunoglobulin A
     
63. Diagnosis of chronic obstructive pulmonary disease
     
64. Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
     
65. Aerosol composition comprising formoterol
     
66. Method for treating respiratory distress syndrome
     
67. Administration of resveratrol to treat inflammatory respiratory disorders
     
68. High storage stability inhalable compositions
     
69. Method for identifying increased risk of death from community acquired pneumonia
     
70. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
     
71. Compositions having improved delivery of actives
     
72. Preventing airway mucus production by administration of EGF-R antagonists
     
73. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
     
74. Method for maintaining or improving the synthesis of mucins
     
75. Nasal spray compositions
     
76. Use of intracellular calcium chelators to increase surfactant secretion in the lungs
     
77. Intratracheal administration of lysozyme
     
78. Modulation of .gamma..delta. T cells to regulate airway hyperresponsiveness
     
79. Labeled humanized anti-CD18 antibodies and fragments and kits comprising same
     
80. Human gene relating to respiratory diseases and obesity
     
81. Bronchodilating compositions and methods
     
82. Nasal spray for decongesting nasal passages
     
83. Methods and compounds for the treatment of mucus hypersecretion
     
84. Compounds from moraxella catarrhalis
     
85. Transdermally administered acetylcysteine as mucolytic agent
     
86. Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation method
     
87. Conjugate vaccine for nontypeable Haemophilus influenzae
     
88. Cell-based gene therapy
     
89. Mixtures of oxygen and helium for the treatment of respiratory insufficiency
     
90. Aerosols containing annealed particulate salbutamol and tetrafluoroethane
     
91. Preventing airway mucus production by administration of EGF-R antagonists
     
92. Ionic aqueous composition containing levomenthol
     
93. Method for treating infectious respiratory diseases
     
94. Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections
     
95. Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
     
96. Method of intranasal gene transfer for protection against respiratory infection
     
97. Method of detecting chlamydia pneumoniae gene using polynucleotides
     
98. Budesonide particles and pharmaceutical compositions containing them
     
99. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
     
100. Composition for treatment of a bacterial infection of an upper respiratory tract
      
101. Gene therapy for pulmonary edema using adenovirus vectors encoding Na,K-ATPase
     
     
102. Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
     
     
103. Antitussive compositions
     
     
104. Method for treating infectious respiratory diseases
      
     
105. Use of bacterial phage associated lysing enzymes for treating streptococcal infections of the upper respiratory tract 
      
106. Integrated lung therapy method
      
     
107. Therapeutic agents for respiratory diseases
      
     
108. Production of virus and purification of viral envelope proteins for vaccine use
      
     
109. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
      
     
110. Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
      
     
111. Immunogenic compositions comprising cold-adapted attenuated respiratory syncytial virus mutants
      
     
112. Xylitol nose spray
      
     
113. Preparation of a pulmonary surfactant for instillation and oral application
      
     
114. Use of inhaled retinoids in the prevention of cancer
      
     
115. Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
      
     
116. Therapeutic method for reversing hyposmia in a human patient
      
     
117. Reduction of surfactant inactivation in pulmonary surfactant therapy
      
     
118. Therapeutic nasal inhalant
      
     
119. Single-dose antihistamine/decongestant formulations for treating rhinitis
      
     
120. Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction
      
121. Methods, compositions and modes of delivery for the treatment of emphysema using 13-cis-retinoic acid
      
122. Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD)
      
123. Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
      
124. Lung surfactant compositions with dynamic swelling behavior
      
125. Method for detecting bacterial exacerbations of chronic lung disease
      
126. Inhalatory compositions of Formoterol
      
127. Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene
      
128. Treatment of acute lung injury and fibrosis with antagonists of .beta.6-specific antibodies
      
129. Use of mometasone furoate for treating airway passage and lung diseases
      
130. Preventing airway mucus production by administration of EGF-R antagonists
      
131. Therapies for treating pulmonary diseases
      
132. Expression of cloned genes in the lung by aerosol and liposome-based delivery

Treatment, Rabies

1. Rabies virus vector systems and compositions and methods thereof
    
2. Binding molecules capable of neutralizing rabies virus and uses thereof
    
3. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
    
4. Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife
    
5. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS

Treatment, Radiation Toxicity/Therapy

1. Ionizing-radiation-responsive compositions, methods, and systems
    
2. Oral compositions and methods for prevention, reduction and treatment of radiation injury
    
3. System and method for the large scale labeling of compounds with radiohalogens
    
4. Targeting drug/gene carriers to irradiated tissue
    
5. Skeletal-targeted radiation to treat bone-associated pathologies
    
6. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
    
7. Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
    
8. Methods for therapy of radiation cutaneous syndrome
    
9. Compositions and methods for reducing radiation and drug resistance in cells
    
10. Method for assaying clustered DNA damages
     
11. Use of adeno-associated viruses for decreasing the radiotherapy-induced or chemotherapy- induced resistance in cancer patients
     
12. Peptide with radio protective effect
     
13. Method for reducing radiation toxicity